Evidence map›Paper›PMID 39072081›Full record

ArticleACS omega2024

Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase.

Sathish K Mudedla, Hayoung Lee, Jeom Ji Kim, Seong Hun Jang, Munikumar R Doddareddy, Swetha Y Sanam, Rochish Gundabathula, Jang-June Park, Sangwook Wu

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sathish K MudedlaPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.ORCID https://orcid.org/0000-0003-3173-5993
Hayoung LeeDrug Discovery Division, ISU Abxis, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea.
Jeom Ji KimDrug Discovery Division, ISU Abxis, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea.
Seong Hun JangPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.
Munikumar R DoddareddyPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.
Swetha Y SanamPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.
Rochish GundabathulaPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.
Jang-June ParkDrug Discovery Division, ISU Abxis, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea.
Sangwook WuPharmCADD, 224, Engineering Building 7, Sinseon-Ro 365, Namgu, Busan 48548, Korea.ORCID https://orcid.org/0000-0001-5794-9477

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allosteric inhibitors of mitogen-activated protein kinase 1 (MEK1) reveal distinct interactions with MEK1 activation loop residues. The structural analyses will determine whether, and how, distinct inhibitors suppress the phosphorylation of MEK1 and may guide future therapeutic development. In this study, we explored the suppression mechanism of the phosphorylation process in the presence of MEK allosteric inhibitors, such as selumetinib, trametinib, cobimetinib, and CH5126766, by employing molecular dynamics simulations accompanied by principal component analysis. The simulations of wildtype MEK1 show that Ser222 can come close to γ-phosphate but not Ser218. We have found the conformation where Ser222 is within 5 Å of distance, which makes Ser222 accessible for γ-phosphate. The conformation analysis from the simulations of MEK1 in the presence of allosteric inhibitors reveals that the inhibitor restricts the flexibility of Ser222 through strong interactions with the activation loop, Lys97, and water mediates interactions with amino acids in the vicinity. The results reveal that all the inhibitors act as screeners between the activation loop and Mg-ATP and restricting the flexibility of the activation loop through strong interaction causes the suppression of the phosphorylation process of MEK1. The results conclude that a strong interaction of allosteric inhibitors with the activation loop restricts the movement of Ser222 toward Mg-ATP, which could be the dominant factor for the suppression of phosphorylation in MEK1. This research will provide novel insights to design effective anticancer therapeutics for targeting MEK1 in the future.

Identifiers

PMID39072081
PMCPMC11270731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.